Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary
February 25, 2021
Earnings Call Speaker Segments
Diane Weiser
executiveGood afternoon, and thank you for being with us on today's call. Robert Blum, who serves as our President and Chief Executive Officer, is going to open things up by walking through our priorities for 2021, taking into account how the company performed during 2020. After that, Fady Malik, our EVP of Research and Development, will give everyone a more thorough update regarding omecamtiv mecarbil, which will include perspective on supplemental analyses from GALACTIC-HF that were presented recently, the favorable Phase III clinical trial of omecamtiv mecarbil, and where things stand with METEORIC-HF, the second Phase III clinical trial of omecamtiv mecarbil. Following him, Stuart Kupfer, our SVP and Chief Medical Officer, will share an update about our cardiac myosin inhibitor program; after which Robert Wong, our VP and Chief Accounting Officer, will walk through a financial overview covering the quarter that just ended; and Ching Jaw, our SVP and Chief Financial Officer, will talk about 2021 financial guidance along with corporate Development strategies, and then Robert Blum will come back to offer closing thoughts about the year ahead and the key milestones we expect for 2021. Kindly be aware that parts of the discussion that follows, which includes how we answer questions, include statements tied to future events and performance instead of historical facts, and those constitute forward-looking statements. What actually happens for us could differ materially from what these forward-looking statements project. Further details about factors that might cause our actual results to differ materially from what those forward-looking statements indicate can be found in our SEC filings, including the current reports we filed on Form 8-K this morning; we under tail obligation to update any forward-looking statements after this call. And at this point I'll hand the call over to Robert.
Robert Blum
executiveThank you, Diane, and I want to express my appreciation once more to all of you for being with us on today's call. As 2021 gets underway, I hope that you and your loved ones are in good health and doing well, even as the COVID-19 pandemic continues to affect all of us. That's true notwithstanding the difficulties presented by stay-at-home directives, pauses and resumptions of clinical trials, and the transition involving our collaboration for development and commercialization that has been in place the longest. We started this year leading the field in muscle biology research, equipped with the most advanced pipeline ever in our company's history and a robust balance sheet, and we are now getting ready for interactions with FDA regarding what could become our first potential NDA submission and what might pave the way for our first approved medicine. In the wake of the favorable Phase III results from GALACTIC-HF, our top near-term goal is to obtain FDA input so that we can bring clarity to a possible regulatory filing for omecamtiv mecarbil in the United States during the second half of 2021. We anticipate sitting down with FDA within the coming weeks, and at the same time, we will finish the work streams already in progress that are aimed at product, market, and sales analyses, which will shape our go-to-market strategy and commercial readiness efforts during the first half of the year. As we made known at the close of 2020, global rights for development and commercialization of omecamtiv mecarbil and CK-136, previously called AMG 594, are coming back to Cytokinetics. Although we did not foresee this, we think it gives Cytokinetics the freedom to operate as we map out our own commercial route ahead and prepare the foundation for the cardiovascular franchise plans we introduced last summer during our Analyst and Investor Day; with that in mind, we also anticipate pursuing business and corporate development efforts this year to find commercialization partners in Asia, in Europe, and potentially for co-promotion within the United States. These efforts are already in motion as we kick off our outreach campaigns, and Ching will go into greater detail about our overall corporate development approach shortly. In addition, during this year, we will keep prioritizing development of CK-274, our next-generation cardiac myosin inhibitor; in December, we reported completion of an interim analysis of Cohort one of REDWOOD-HCM, the ongoing Phase II clinical trial of CK-274 that we are conducting in patients with symptomatic obstructive hypertrophic cardiomyopathy. Findings from that interim analysis supported moving ahead to Cohort 2, which began screening in December. And I am happy to share today that enrollment in Cohort 2 is now complete, and we anticipate having top line results from both cohorts by midyear 2021. As this year moves forward, we will lay out our plans for potentially advancing CK-274 into Phase III during the second half of the year. Stuart will give you specifics about the interim analysis and where our thinking currently stands regarding the continuing development program. While our 2021 focus will center on cardiovascular efforts, after gaining clarity regarding the go-to-market approach for omecamtiv mecarbil and moving CK-274 forward into Phase III, we would at that point look at launching enrollment for COURAGE-ALS; this is the Phase III study we have planned for reldesemtiv involving ALS patients, which could allow us to further grow our late-stage pipeline. Even with difficulties created by the ongoing pandemic, our research organization keeps delivering. Because of how committed our scientists are, we expect to push extra compounds—possible development candidates coming out of research—ahead into development within the next one to two years; we look to apply our leading knowledge in muscle contractility to broaden into additional areas of muscle function, possibly reaching toward potential therapies for other severe but related illnesses and conditions, and we will share more on that topic later this year. For Cytokinetics, 2021 could prove to be a year of transformation, since we are getting ready to potentially file our very first NDA, which might result in bringing our first medicine to market for heart failure patients. Also, as described in our Vision 2025, unveiled early last year, our aim across the coming five years is to secure possible regulatory approvals for no fewer than two drug candidates coming from our pipeline and to move toward lasting product-based revenues, while at the same time doubling our pipeline of development programs and intending to broaden our discovery platform past muscle contractility. Given how strongly we performed in 2020 and the momentum we already see in 2021, we feel we are progressing well. With that said, I will hand the call to Fady so he can go into more detail about omecamtiv mecarbil developments.
Fady Malik
executiveThank you, Robert. In November 2020, results from GALACTIC-HF, which is our Phase III trial of omecamtiv mecarbil, were shared at the American Heart Association conference, and later they appeared in the New England Journal of Medicine. Since we've already covered those results in considerable detail, I'll start by summarizing the additional analyses presented by the Executive Committee Chair, Dr. John Teerlink, during the Global Cardiovascular Clinical Trialist Forum, also known as the CVCT meeting, which took place in December. After that, I'll share some thoughts on which patients, based on these data, stand to benefit most from treatment with omecamtiv mecarbil. If you recall, our GALACTIC-HF results at the top level demonstrated a treatment effect from omecamtiv mecarbil that was statistically significant when it came to reducing the risk tied to the primary composite end point — namely, the time until a first heart failure event or death from cardiovascular causes — when compared with placebo in patients receiving standard of care. While the secondary endpoint measuring time to cardiovascular death did not show a reduction across the full population, the study nonetheless met its primary efficacy endpoint with statistical significance in that overall population, which comprised over 8,000 patients enrolled throughout 35 countries globally. When looking at the majority of the predefined subgroups, the impact of omecamtiv mecarbil remained consistent, and there was a suggestion of a possibly greater treatment benefit in the group of over 4,000 patients whose left ventricular ejection fraction measured at or below the median value of 28%. At CVCT, extra analysis of the subgroup with lower ejection fraction showed that the possibly larger treatment benefit for patients who received omecamtiv mecarbil showed up consistently among those whose features might suggest a more advanced stage of heart failure — such as a hospitalization within the previous three months, New York Heart Association Class III or IV heart failure, elevated NT-proBNP levels, or reduced blood pressure; and looking at the absolute risk reductions in these sizable prespecified subgroups, they are reasonably substantial, ranging from 5.2% to 8.1%. Also, when we examined ejection fraction as a continuous variable alongside the hazard ratio for the primary composite endpoint in GALACTIC-HF, the findings suggested that omecamtiv mecarbil might deliver a larger treatment benefit to patients with progressively lower ejection fractions. Because the main action of omecamtiv mecarbil is to enhance cardiac function, it stands to reason that those with lower ejection fractions would gain more. These findings are important, since we recognize that these sicker patients with more advanced heart failure continue to carry significantly elevated risk even when receiving standard of care therapy, and as the disease advances, they frequently are unable to tolerate guideline directed medical therapy. Often, this group is the toughest to treat, and they may cycle in and out of the hospital repeatedly. So a clearer image is emerging: omecamtiv mecarbil might provide a fresh therapeutic choice for these very sick heart failure patients. Biologically speaking, it stands to reason that those with worse systolic function would see more advantage from adding this innovative mechanism therapy to their usual care. Unfortunately, those individuals are not receiving COD, and they might represent more than 50% of the 3 million patients who have heart failure with reduced ejection fraction today. These people often wind up in our hospitals, which keeps increasing the clinical and economic strain on our system. When their condition worsens even with the medical treatments we currently have, there isn't much we can offer them. Since sharing the GALACTIC-HF findings, we've been able to talk with close to 200 health care professionals, including prominent heart failure opinion leaders, investigators, and community cardiologists. What we've heard back has been uniformly encouraging, and people are behind our effort to secure regulatory clearance built on the GALACTIC-HF findings, the safety data for omecamtiv mecarbil, and the gap in care that exists for patients whose heart failure is further along. In the previous quarter, the FDA made notable moves in the heart failure space. We view the recent label expansion for Novartis's Entresto, covering heart failure with preserved ejection fraction, along with the agency's recent clearance of vericiguat, or vercuva, as encouraging. From our perspective, these events underscore how much unmet need remains in heart failure even with guideline directed medical therapies available. We also think these events may bode well for omecamtiv mecarbil, because of its novel muscle-directed action and the net GALACTIC-HF results seen on top of standard of care. As we have said, Cytokinetics remains committed to advancing omecamtiv mecarbil as a priority in 2021. On that note, our initial meeting with the FDA regarding regulatory matters is set to take place prior to the close of this quarter. As these regulatory discussions proceed and we finish the transition work still underway with Amgen, we anticipate sharing updates about this and upcoming regulatory engagements, and we also expect to verify the timeline we've projected for a possible NDA filing with the FDA during the latter half of 2021. At the same time, METEORIC-HF continues to move forward—it does not sit on the essential pathway toward NDA submission—and we anticipate that enrollment will wrap up during the first six months of this year. Last, as part of the work we're doing on cardiac myosin activators, we're getting back the rights to develop and commercialize CK-136, which used to be called AMG 594 — a cardiac troponin activator that's first in its class. Following up on the Phase I trial Amgen ran, we'll look at which additional Phase I studies might be needed before this candidate can move forward. That said, as Robert said before, omecamtiv mecarbil is still the bigger priority for us in 2021. So with that, I'll hand things over to Stuart, who will give an update on the cardiac myosin inhibitor program.
Stuart Kupfer
executiveThanks, Fady. When the previous quarter wrapped up, we moved REDWOOD-HCM into Cohort 2, after an interim analysis came back positive. The purpose behind REDWOOD-HCM was to assess what advantages might come from CK-274, our cardiac myosin inhibitor belonging to the next generation, for individuals dealing with disruptive HCM alongside symptomatic heart failure. As a refresher on how the trial was set up, participants went into either placebo or CK-274 according to a 2:1 randomization. In Cohort 1, people received once-daily amounts of 5, 10 or 15 milligrams, or placebo, and each person's titration was decided separately, aiming to hit particular echocardiographic targets. Every two weeks, dosing was tweaked across a 6-week span, and treatment lasted 10 weeks in total. Data from Cohort one's interim analysis revealed that participants saw major drops in the average resting and less ventricular outflow tracked radiants. These decreases in pressured radiants, clinically relevant as they were, came alongside only modest declines in average left ventricular ejection fraction. Crucially, no doses had to be stopped because ejection fractions dropped under 50%, a safety threshold that had been prespecified. The pharmacokinetic profile matched what had been seen during Phase I among healthy subjects. Moreover, safety and tolerability findings backed continuing to escalate doses, since investigators reported no serious adverse events tied to study treatment. Following the December review of interim results from Cohort 1, the Steering Committee and the Data Monitor Committee of REDWOOD-HCM advised moving the trial ahead into Cohort 2, and I'm happy to share that enrollment for the second cohort is now finished. Those in Cohort two receive escalating doses of 10, 20 or 30 milligrams, or placebo, once daily. Top line results from the trial should be reported around midyear, with complete data set to be shared at a medical meeting coming up this fall. While waiting on REDWOOD-HCM results, we're already getting ready to launch a Phase III pivotal trial involving patients who have obstructive HCM, aiming to get that trial underway before year-end; we feel the urgency of delivering novel medicines to HCM patients, for whom no disease-modifying therapies exist to inhibit the underlying hypercontractility that defines the disease, and to boost quality of life and functional capacity. Once Phase II results arrive, our aim is to hold end of Phase II meetings with FDA and EMA during the year's second half so Phase III can begin before end of year. What we want from Phase III is to assess how CK-274 affects patients' symptoms and function, and also to grasp CK-274's long-term safety profile. With that in mind, we'll shortly start enrolling REDWOOD-HCM patients into an open-label extension trial. First, we enroll those who finished taking part in Cohort 1, then we roll over patients currently in Cohort 2. In the same way, patients taking part in our Phase III pivotal trial will get the chance to join the open-label extension trial. Looking ahead, tracking these patients over time is going to help us grasp how well CK-274 works and how safe it is, and it will also let us evaluate whether CK-274 could have an impact on reverse remodeling, as measured through cardiac imaging. On top of that, our work with Ji Xing has moved ahead quickly toward the goal we share: making it possible to bring China into a worldwide Phase III trial of CK-274 in people who have obstructive HCM. The IND we filed in China for the Phase I trial of CK-274 has gotten the green light, and we expect that study to kick off in the first quarter. As part of the broader strategy for developing cardiac myosin inhibitors, we also kept evaluating CK-271, our other cardiac myosin inhibitor, over the quarter. Thanks to a single ascending dose study conducted in healthy volunteers, we now have a clear picture of the pharmacokinetic profile of CK-271. Although those data support moving development forward, our priority is pushing CK-274 ahead quickly, and we expect to know by year-end where we stand on Phase II plans in a different indication, whether that's nonobstructive HCM or a subgroup of heart failure patients with preserved ejection fraction; down the road, we might look at advancing CK-271 for another indication that falls outside the scope of CK-274. That's the benefit of one of the central features of how we approach R&D: creating backup, follow-on and next-generation compounds so we keep as many options as possible open and raise the odds of success. With that, I'll hand things over to Robert Wong, who will give you an update on our financials.
Robert Wong
executiveThanks, Stuart. To start, I'll give you an update on our cash position, revenue, and spending, and after that Ching will walk through our financial and corporate development strategies looking ahead. You can find the details on our actual results for the fourth quarter of 2020 in the press release that went out earlier this afternoon. We closed out the fourth quarter with roughly $501 million in cash and investments. That balance includes $85 million that came in when we completed the sale of a royalty on mavacamten to RTW Royalty Holdings Designated Activity Company. During Q4 2020, our revenue came mainly from our strategic alliances with Amgen and Astellas, along with an earned milestone payment. R&D expenses for the fourth quarter of 2020 rose to $29.2 million, compared with $18.3 million in the fourth quarter of 2019, largely because of greater spending on our REDWOOD-HCM activities and on readiness work for a possible Phase III trial of reldesemtiv. As we anticipated, over 50% of our R&D expenses stemmed from our cardiovascular programs, given the activity for METEORIC-HF and the cardiac myosin inhibitor program, while the rest of our expenses came mainly from our early research activities. G&A expenses in the fourth quarter of 2020 totaled $13.9 million, an increase from $10.6 million in Q4 2019, driven by higher personnel-related costs, including stock-based compensation, as well as greater commercial readiness spending. And with that, Ching will now review our 2021 financial guidance and corporate development strategy.
Ching Jaw
executiveRobert, thank you. We released our 2021 financial guidance earlier today. For 2021, the company expects revenue between $23 million and $28 million. Operating expenses should fall somewhere between $195 million and $205 million, while net cash utilization is projected at roughly $160 million to $170 million. Based on our projected operating expenses and this net cash utilization range, our present cash balance of $501 million equates to over two years of forward cash. Within our net cash utilization range sits approximately $35 million tied to nonrecurring building construction and related capital expenditures. That range also factors in the possible receipt of $45 million from RTW Royalty Holdings Designated Activity Company, which would come in exchange for a low single-digit royalty on CK-274 under the funding agreement signed in July 2020, assuming the conditions for payment get satisfied. If we choose not to exercise our option for that $45 million, then we would expect our net cash utilization range to go higher. Later in the year, after we finalize our strategy and potential commercial launch plan for omecamtiv mecarbil, we may update this guidance. Carrying out those strategies and plans could generate significant additional expenses and net cash utilization that fall outside the guidance. Such additional expenses include, without being limited to, purchasing drug substance for omecamtiv mecarbil from Amgen and other costs tied to transitions away from Amgen, funding development and regulatory activities for the immuno assay used in GALACTIC-HF and METEORIC-HF to determine omecantiv mecarbil dose levels, plus other potential commercial planning and readiness activities. Our aim is to finish 2021 with over two years of forward cash. While getting ready for possible commercialization of omecamtiv mecarbil and pushing forward the clinical development of CK-274, we have already started carrying out our corporate development strategy. That strategy has two parts: first, finding a development and commercialization partner for omecamtiv mecarbil and CK-274 in Japan and other geographies; and second, exploring potential royalty monetization and/or structured financing deals to support the commercial launch of omecamtiv mecarbil. As we move forward with commercialization plans for omecamtiv mecarbil, which we believe will importantly establish a strong foundation for commercialization of CK-274 and the expansion of our cardiovascular franchise, we are examining comparable company best practices and assembling a fit-for-purpose commercial organization. Once our target product profile comes into focus, we will be putting together pricing models, forecast and profitability assessments to inform our U.S. and European go-to-market strategies, including investment and partnering or co-promotion plans. As ever, we expect to steer our key corporate development decisions through the lens of maximizing potential values to our shareholders. With that, I'll hand the call back to Robert Blum.
Robert Blum
executiveThank you, Ching. In 2021, we've stepped into what may prove to be a year of transformation for Cytokinetics, as we get ready for the possible marketing authorization and commercialization of our very first medicine, while at the same time moving several drug candidates forward across different phases of clinical development. All of this aligns with our Vision 2025, which we laid out at the beginning of last year — a vision that sets forth goals that are ambitious, yet in our view attainable: to commercialize no fewer than two new medicines, to build sustainable revenues generated by products, and to both grow our discovery platform and double the count of our development programs, reaching 10 by 2025. As we mentioned today, the first step toward realizing that vision is working with regulatory authorities and getting ready for the possible commercialization of omecamtiv mecarbil. Teams of ours are carrying out multiple work streams — refining the target product profile and figuring out the right sizing, structure, and territory alignment for our sales organization so that customer engagement is optimized in a world after COVID. We're drawing on a mix of applied analytics and lessons from recent cardiovascular launches to decide how we ought to engage with physicians, whether through face-to-face conversation, digital dialogue, or both. What matters here is that we're putting together a sales organization aimed at the busy heart failure hospitals and the specialty cardiology clinics nearby, and it will also take on the market access work needed to connect with advanced heart failure patients across the U.S. — and we may bring in a copromotion partner to help outside the focused segment we're targeting. On top of that, since high-volume heart failure centers and HCM centers work so closely together, the money we spend will be spread across our whole cardiovascular franchise, which sets up a solid base for cross-promoting CK-274 later on. Additionally, we're working alongside top academic centers and health care systems on a thorough health economics and outcomes research initiative. The goal is to shed light on the toll that advanced heart failure patients impose on the health care system, and on how omecamtiv mecarbil could bring about economic relief in addition to clinical relief by cutting the expense of rehospitalizations. Payers will certainly pay attention to this, given that hospital administrators are dealing with penalties for rehospitalization occurring within 30, 60 and 90 days after discharge when heart failure is the diagnosis. With REDWOOD-HCM results anticipated at midyear, our plan is to move CK-274 quickly into Phase III for obstructive HCM before the year is over, and to also figure out the next steps for launching a possible clinical trial in either nonobstructive HCM or an HFpEF patient population, with those getting underway in 2022. We think carrying out these initiatives matters a lot if we're going to keep our corporate plans in proper balance, and it also helps shape how we view our cost of capital along with the enterprise risk-benefit down the road. We're also aware of the role we play in the pressing need to assist ALS patients, and we stay hopeful about kicking off our Phase III clinical trial of reldesemtiv in ALS patients sometime later this year. That said, it hinges on gaining regulatory clarity regarding the path forward for omecamtiv mecarbil, plus having visibility into results from REDWOOD-HCM and our related cost of capital. And, a short while back, we were glad to welcome Nancy Wysenski and Muna Bhanji onto our Board of Directors. Each brings substantial experience and know-how in commercial strategy, market access, and particularly specialty sales, gained through leadership positions at Vertex and Merck, respectively, along with other organizations. Their recent, pertinent experience steering through the changing access environment and other challenges for patients facing high unmet needs will be extremely valuable, we're confident, as our pipeline moves toward marketing authorization and commercialization. We're eager to share updates on our progress during this year, since our leadership and the mechanics of muscle and contractility could lead to new medicines—medicines that might assist patients suffering from devastating diseases involving impaired muscle function and enhance their health spend. Now, allow me to summarize the milestones we anticipate for 2021. On the omecamtiv mecarbil front, we're looking to sit down with the FDA in Q1 of 2021 to discuss GALACTIC-HF. Beyond that, during the opening six months of 2021, we expect to shape how we'll bring the product to market along with any launch plans that make commercial sense. Also in that same first-half window, we expect heart failure patient enrollment for METEORIC-HF to be finished. Turning to CK-136, our plan for 2021 is to go over the Phase I results so we can determine what the next phase of development looks like. As for CK-274, a Phase I trial in China — run through the licensing and collaboration arrangement Cytokinetics has with Ji Xing Pharmaceuticals Limited — should get underway in the first quarter of 2021. For those completing REDWOOD-HCM, we expect to kick off an open-label extension study during Q2 of 2021. Data from the two cohorts in REDWOOD-HCM should be shared by the middle of 2021. During the latter half of 2021, our plan is to discuss with regulators what a potential registration pathway might look like, and we expect that a possible Phase III trial of CK-274 could begin before 2021 comes to a close. Regarding CK-271, we expect to keep evaluating whether there's an opportunity to advance that compound further, while also pursuing a wide-ranging development effort for our cardiac myosin inhibitors in HCM and possibly additional indications. As for reldesemtiv, our expectation is to carry out start-up work for COURAGE-ALS during 2021 and potentially begin enrolling patients in that trial during the latter half of 2021 — all of which remains contingent on our intentions around moving omecamtiv mecarbil toward commercialization, along with CK-274 and a potential Phase III clinical trial involving patients who have obstructive HCM. As part of our continued research efforts, we expect to push programs forward and carry out IND-enabling studies, which could allow us to bring one or two possible drug candidates into development during 2022. With that said, operator, please go ahead and open the line for questions.
Dane Leone
analystHi, hello. How are you?
Robert Blum
executiveGood.
Dane Leone
analystThanks for fielding my questions, and nice work on the progress. I suppose what I want to zero in on is this: when it comes to the FDA interaction regarding omecamtiv, what exactly are you hoping to get out of it so that you have the kind of information needed to make a decision and take that program in one direction? Maybe you could frame that against the bigger conversation investors are having, and the kinds of things we get asked. In your prepared comments you brought up other launches in cardiovascular, and whether it's fair or not, folks do worry about how tough that space can be to launch into. The recent bempedoic acid launch is something some might point to as an illustration. At this stage, do you already have an internal model with a view on peak sales for the omecamtiv launch, or is that still TBD until after you've talked with the FDA? How long did it take to reach that point? And then, in what year of the launch would the commercial product actually turn a positive margin? Thank you.
Robert Blum
executiveSure; Dane, that's a whole lot to pack into a single question. Let me do my best, and I may ask my colleagues to chime in. There are parts I can address. Other parts clearly are premature; as for the upcoming FDA meeting, the purpose is to go over the GALACTIC results, and it won't function as a pre-NDA meeting in any other respect. Our expectation is actually a series of regulatory interactions, beginning in this first quarter and carrying on into the second quarter, which in the end will shape our possible filing of an NDA during the second half of the year. At this initial meeting, though, our aim is to discuss GALACTIC and find out whether they view it as adequate and appropriate to stand alone in backing a possible NDA filing and a possible marketing authorization; so we'll go through the data with them, as we're ready to do in its comprehensive form. Ideally that informs whether this will be pre then supportive of what could be second and third meetings that we may anticipate later in the second quarter; so that's what this meeting is meant to accomplish. Fady, is there anything you'd like to add before I move on to the remaining points.
Fady Malik
executiveNo, I think you covered it fine, Robert. Thanks.
Robert Blum
executiveAll right. So, Dane, you raised quite a few questions regarding our go-to-market approach and the timing around when we could potentially offer clarity on profitability and similar matters. Naturally, models do exist on our end, and we're continuing to sharpen them. As a matter of fact, at this very moment we're transitioning away from certain earlier qualitative market research efforts — work built around a set of target product profiles drawing on the GALACTIC data — toward more quantitative market research, which is going to shape forecasting, price sensitivities, and so forth. To address your question directly, at the end of the day we need clarity on how the infrastructure required to back commercialization would take shape. My own view is that nothing else being launched really mirrors what we envision, even though other cardiovascular launches do exist; and I accept your point that a number of those launches came in below expectations, so lessons ought to be drawn from them. That said, the manner in which we're moving forward — and plenty of us bring hands-on, relevant experience with this kind of commercialization work — the manner in which we're moving forward, we believe, could allow omecamtiv mecarbil to work alongside currently available drugs, yet aimed at patients lacking any other solid options, and our aim would then be to demonstrate safety, efficacy, and economic value together with that, as it would constitute a highly concentrated, tractable commercial market in which those patients carry the greatest burden — namely, within the institutional care setting, where such patients tend to receive treatment from nearby specialty cardiologists whose focus is advanced heart failure. So you don't require many hundreds — and certainly not thousands — of reps in order to connect with those patients and those physicians, particularly once you grasp where high-yield returns can be found. Thanks to AI and digital marketing, our expectation is to assemble a fit-for-purpose organization suited to a post-COVID world. And we genuinely believe certain go-to-market strategies ought to be within our financial reach and deliver prompt visibility into profitability. How soon? That truly hinges on factors I really shouldn't be speculating about right now; however, we do anticipate setting out a go-to-market strategy at midyear this year to support our plans for omecamtiv mecarbil, and I expect we'll be able to offer further clarifying details at that point.
Dane Leone
analystThank you very much.
Robert Blum
executiveThanks, Dane.
Jason Butler
analystHello, and thank you for allowing me to ask. I have a few questions regarding 274. Now that the initial cohort of the Phase II trial is behind you, could you share some perspective on the various factors involved in designing a Phase III study? Naturally, we must await the complete dataset, but what are the competing considerations you are weighing? Perhaps you could also draw a comparison with the EXPLORE trial for mavacamten. Additionally, what factors come into play when you evaluate the subsequent steps for another indication for 274, whether that be nonobstructive HCM, HFpEF, or a comparable condition? Which key elements are you still examining? Thank you.
Robert Blum
executiveCertainly. That is a good question. I will have Fady and Stuart respond to those points, though first I want to emphasize something. The swift pace at which Cohort two was enrolled in REDWOOD-HCM demonstrates considerable excitement surrounding this mechanism and CK-274, among institutions both within the U.S. and outside the U.S. that are signing up patients for REDWOOD-HCM and from whom we would grow in a possible Phase III program. Having said that, I will pass it to Fady and Stuart so they can discuss how that Phase III program might be structured. Certain aspects can be disclosed at this point. Others, clearly, will remain confidential for the time being, and then also our approach to additional indications. Fady?
Fady Malik
executiveAbsolutely, and I'll take the first portion of what you asked, Jason. When it comes to Phase III, a key advantage we're aiming to leverage is that CK-274 is easier to titrate, which lets us build endpoints focused on resolving symptoms sooner, boosting exercise capability, simplifying dose escalation, and similar goals. So the REDWOOD results will really help us figure out how to adjust the scheduling for evaluating those items, shape the Phase III design, and refine escalation thresholds and so on. That said, as Robert mentioned, design work is still ongoing right now. We've got some promising concepts. And when we do kick off a study, we'll likely work to ensure everyone grasps how our Phase III differs from how EXPLORER was run. Now I'll hand things to Stuart so he can share our thinking on NHCM, or HFpEF.
Stuart Kupfer
executiveOkay, so what I was about to say is that the design for the obstructive HCM trial is definitely going to hinge on what we learn from REDWOOD-HCM. And as Fady mentioned, we want to make the most of the chance to show a difference compared with mavacamten. I'm bringing this up in that way because REDWOOD-HCM is also going to help shape our approach in nondisruptive HCM or HFpEF. We've talked before about certain characteristics of nonobstructive HCM that could point to a benefit in a subset of patients who have HFpEF. So a great deal of this decision-making really depends on what REDWOOD-HCM shows us and where the greatest opportunity appears.
Jason Butler
analystAlright, that's really useful. Appreciate you answering our questions.
Stuart Kupfer
executiveThanks, Jason.
Robert Blum
executiveHey, Joe.
Joe Pantginis
analystHello, everybody. Appreciate you taking my question. Given how much BD has featured in the remarks you prepared for today, I'd like to zero in on that. Perhaps we could begin with how those conversations have unfolded and progressed. To start, how quickly after Amgen handed the asset back did any possible talks get underway? Then, jumping ahead to the present: it appears significant, when it comes to timing, that a prospective partner might wish to occupy what you could call the co-pilot position — regarding commercialization and expansion into additional geographies, or perhaps even co-promoting within the U.S., especially since the NDA isn't all that distant?
Robert Blum
executiveRight. Those are excellent questions. I'll kick things off, then check whether Ching has anything to contribute too. Right after the notice arrived from Amgen, we got these conversations going without delay — though I should qualify that by noting some items simply aren't ours to disclose, since our Amgen collaboration is in the process of winding down and will formally conclude in May of this year. That means confidential materials are off-limits during this interim stretch, while non-confidential materials may be shared before then — though that pertains to omecamtiv mecarbil. When we consider business development alongside corporate development, the two are intertwined; our aim is to give priority to partnering in ways that could allow omecamtiv mecarbil and CK-274 to be combined, and for CK-274 we face no comparable restrictions, with attention directed at Japan and Europe ahead of co-promotion in the U.S. So our sense of what we want is extremely well-defined. And you're correct that a prospective partner might be interested in copiloting some of those efforts, yet we also recognize that we hold the lead position here, and we're able to shape a potential partnership toward terms we'd consider acceptable by continuing to advance these initiatives. In this instance, we want to be sure our go-to-market strategy is clear and that we understand what the regulatory feedback says, so we can pinpoint the strongest possible partner on suitable terms. Nor does that reality prevent us from holding discussions regarding royalty monetization and structuring deals; with that said, I'll pass it to Ching and let him expand on some of those ongoing conversations.
Ching Jaw
executiveYes. Thank you, Robert. So talks have kicked off with a number of parties on two fronts — one being possible business development agreements, and the other being royalty monetization or structured financing arrangements. I'd simply note that you could check out transactions we completed previously with firms such as Royalty Pharma and others — at RTW — to get a feel for the sort of deal structure we may be going after when it comes to royalty monetization and structured financing. I'll leave it at that.
Joe Pantginis
analystNo. That really helps, and I appreciate the color. Then, clearly, a lot rides on omecamtiv, but I was just wondering whether you could give a bit more detail on the gating factors for moving reldesemtiv ahead?
Robert Blum
executiveSure. So the study we've set out for reldesemtiv, known as COURAGE-ALS, has design elements that let it be halted or adjusted for interim analyses. Because of that, if what we expect to see in that study isn't showing up, we could pull the plug, or we could actually increase some of the patient enrollment too. That applies to a study whose costs we've fully calculated and where a meaningful share of the expense would be covered by our partner, Astellas, in return for a royalty in the low single digits. So we think this is a study that's affordable; yet at the same time, we know our priorities have to stay centered on omecamtiv and CK-274, particularly since those will demand more spending and also shape our cost of capital; so we want all of the information available when we decide to launch that study. And in the interim, we can carry out start-up activities that would be helpful when we do begin that study so that it finishes on roughly the same timeline. So we view this as a prudent investment within the balanced way we're handling our portfolio, knowing that priority number one is omecamtiv, priority number two is CK-274, priority number three is reldesemtiv; but we do expect that all three should be moving forward during the second half of the year.
Joe Pantginis
analystGot it. Thanks a lot guys.
Robert Blum
executiveThank you.
Robert Blum
executiveHello there, Salim.
Salim Syed
analystHi, Robert. What's going on with you?
Robert Blum
executiveI'm well.
Salim Syed
analystA couple from me, if I may, and they're likely aimed at Fady or possibly Stuart. Regarding the CK-274 guidance, I saw that you referenced something comparable to PK data, and you've discussed meaningful drops in LVOT gradient. I'm simply wondering whether you folks are already at the point you'd like to be with Cohort 1, or whether you believe Cohort two will be necessary here. The reason I ask is that you're already discussing launching pivotal trials. So I'm just wondering how you're viewing that data set, since you've already observed meaningful drops at four to six weeks. My other question also concerns 274. For the top-line data we'll receive in the middle of the year, could you perhaps walk us through what you intend to include in the press release? Will it be more of a placeholder-style press release, or will there be something of substance in there that investors can actually use? Then one unrelated item on 136 — my impression is simply that you folks appear somewhat reluctant about advancing this troponin activator. You may want to conduct additional Phase I studies, and I'm curious about what you're observing there. Given where omecamtiv stands, I'd have thought you'd want to push a troponin activator through the pipeline more rapidly.
Robert Blum
executiveYes. Let me begin, and after that I'll hand things over to Fady and Stuart. I'll likely address your questions in reverse sequence. So regarding CK-136, we're in the middle of those transition talks with Amgen, and we still have to evaluate that data and determine whether anything further should be completed in line with additional Phase I development before we commit to how Phase II might be conducted. I expect there will be additional activities required to get ready for Phase 2; however, please don't interpret that as us being any less excited about its potential, because that isn't the case. The reality is that we have something of an embarrassment of riches when it comes to our capacity to fund and prioritize everything simultaneously. And I genuinely believe we'll figure out a way to put together a plan for CK-136, though in priority order relative to the other programs we've discussed. And also regarding how we'll report the results from REDWOOD when we do? Without the data in hand, giving a firm answer is difficult, yet my expectation is that it lands somewhere between a bare top-line announcement and what would be kept back for the presentation itself — sufficient to get the results across and lay the groundwork for that presentation; it won't carry the full level of detail that would undermine the presentation, but it should be enough to hopefully give us and shareholders insight into why that might support advancing into Phase III and set it apart from the first-generation product. Having said that, I'll hand things to Fady so he can address your question on Cohort one and whatever else he'd like to include.
Fady Malik
executiveHello, Salim. What I'd say in response is that final dose selection for Phase III draws on both Cohort one and Cohort two. With Cohort 1, it was obvious that we had a group of highly active doses, yet not a single patient achieved a complete treatment response. That explains why we are looking at somewhat larger doses in Cohort two — to raise the share of patients reaching the treatment response. Taken together, the two cohorts will guide the starting dose as well as the high dose that we choose. So my sense is that these are not — they remain on schedule to let us design and launch Phase III before this year is over.
Salim Syed
analystAll right. Thank you very much. That detail is helpful.
Fady Malik
executiveI appreciate it.
Robert Blum
executiveHello, Charles.
Charles Duncan
analystYes, thanks. Hi, Robert, and greetings to the whole team. I appreciate you fielding my questions. A lot of excellent ones have already come up, but I'll take a chance on a few different ones. To start, about that FDA meeting coming up within the next few weeks, my assumption is that you'll hold off until the official minutes are available? Or do you figure the questions you're posing aren't so, say, intricate that you could actually discuss them before this quarter ends?
Robert Blum
executiveWe definitely will want to review those minutes, though I'm not sure that gathering will necessarily lead to additional disclosure so much as an ongoing series of activities. Because of that, we'll need to evaluate what comes out of it once the meeting happens. What we don't plan to do, however, is give a play-by-play on each regulatory exchange and each action tied to the transitions from Amgen, since all of it feeds into a larger picture that we'll share when we believe it's suitably informative, and when those developments become truly material. I hope that answers your question.
Charles Duncan
analystRight, that's correct. So it sounds as though there isn't really a specific issue regarding the clinical plan — maybe holding off for medioric or more clinical data — and instead it comes down to deciding what goes into an NDA?
Robert Blum
executiveNo, that's not what this meeting is for. This initial gathering is genuinely meant to talk about GALACTIC and whether the results back moving ahead to whatever comes next, which would probably be more discussions during a pre-NDA meeting. So over the coming months, we anticipate a number of these meetings taking place. Should we find out that GALACTIC alone wasn't enough to back a filing, or if some other point were that conclusive, then we'd probably feel we had to share that, since it would catch people off guard. However, what we anticipate is receiving guidance that will likely require further elaboration through additional interactions.
Charles Duncan
analystAll right, all right, that's useful. Now for my next question, it's about commercialization. I'll assume everything proceeds smoothly with the agency and omi ends up getting approved. I suppose what I'm curious about is — I believe Fady said you've received excellent feedback from KOLs and other people. Have payers said anything so far? And what would you call the main pharmacoeconomic factor, maybe one or two, that in your view sets omi apart when it comes to generating value for patients and for payers?
Robert Blum
executiveGreat question. We've had conversations with more than 150 key opinion leaders at this point, and what we keep hearing back is remarkably uniform: in their view, the data omecamtiv mecarbil generated in GALACTIC distinguishes it from the other heart failure treatments available today, especially since it enhances cardiac performance and, in GALACTIC, demonstrated activity along with safety and efficacy when added to standard of care in patients who were well managed and sticking to that standard of care. That strikes us as very encouraging. Still, to get at your question directly, there's more to it than that. Our discussions with payers are ongoing, and those conversations will continue across the first and second quarters. What we're hearing back has been positive — they'd welcome a novel therapy that helps patients survive and avoid hospitalization, especially one that reduces the expenses associated with heart failure. And, as you know from GALACTIC, when omecamtiv mecarbil was given alongside standard of care, the main impact we saw was fewer hospital admissions and readmissions, and this occurred in addition to standard of care. The magnitude of that benefit, according to secondary analyses, seems to grow in a way that really matters as patients have more advanced heart failure. That's pretty fascinating and persuasive, and it informs a great deal of the value story and what could function as the health-economic justification for omecamtiv mecarbil after it reaches the market. We believe this may be coming at just the right moment, since those heart failure hospitals face growing readmission penalties — initially 30 days, and now, with public policy efforts, it looks increasingly likely to extend to 60 and 90 days, which would mean any rehospitalization within that window falls on the index hospital's dime. So if omecamtiv mecarbil is started when a patient leaves the hospital, and if it can bring down how often those patients end up back in the hospital, that ought to help not just from a clinical standpoint but from a financial one too. That makes the value proposition especially meaningful, particularly since heart failure ranks as the top reason for discharge among people admitted to hospitals under Medicare, and with an older population, the situation is only expected to worsen. As more analyses and studies get completed, we expect this element to become a growing part of the overall picture.
Charles Duncan
analystRobert, that's useful. Thanks, and I appreciate the considered response. For my final question, maybe I'll direct it to Ching. Ching, you made a number of points, and one of them grabbed my — well, honestly, every one of them grabbed my attention, but the item I recall involves the immunoassay. It stands to reason that your expense guidance really can't be properly grounded before you settle on how to move forward regarding commercialization and other matters tied to omecamtiv in the pipeline. Still, you brought up the immunoassay, and I'd like to grasp that better. So what expense might that involve?
Ching Jaw
executiveCharles, what I'm pointing to there is the current arrangement Amgen has with Thermal Fisher for creating the in vitro diagnostics intended for dose titration of omecamtiv mecarbil. As Amgen exits that arrangement, the presumption is that we'll need to take its place, and talks with Thermo Fisher about how to proceed have only just started. That's the meaning behind what I said regarding the immuneassay.
Charles Duncan
analystUnderstood. We'll get more details afterward, all right. I appreciate you letting me ask my questions.
Robert Blum
executiveThanks.
Jeff Hung
analystThank you for allowing me to ask. Given that the emphasis for omecamtiv mecarbil is on individuals whose ejection fractions are under 30%, what is your present thinking about the best way to connect with that patient population more effectively after omecamtiv reaches the market? And I have one more question after that.
Robert Blum
executiveThese patients can be identified quite readily. You may recall hearing Mike Felker speak during our panel presentation following the GALACTIC results being shared at AHA. Such individuals typically receive treatment not only from cardiologists; more frequently, it is the heart failure specialists who get called in for these frequent flyers at U.S. hospitals. So identifying them isn't hard, and quite often they are familiar faces. In fact, through our ongoing discussions with opinion leaders, that particular patient phenotype remains foremost in many of their minds, since nothing currently in their toolbox could assist those patients who have already hit the floor with respect to blood pressure, kidney function, or potassium levels. That is precisely where omecamtiv's profile could be particularly well suited. Fady, is there anything you would like to add?
Fady Malik
executiveRight. The key thing, I think, is that — as we discussed before — these patients tend to cycle in and out of the hospital frequently. That makes them fairly easy to spot, since they need a greater degree of care. Plus, the doctors treating them usually work in hospital-based settings, among other factors, which makes it easier to reach out to them and get them involved regarding the options that exist for those patients.
Jeff Hung
analystAll right. Regarding the following item, I did hear the question, yet the response escaped me — my apologies if that's on me. Would you mind giving that answer once more? When it comes to the REDWOOD data, which endpoints ought we to anticipate in the top line data? Also, I suppose, what would you need to observe before judging the study a success? Thanks.
Fady Malik
executiveSure, Jeff — I'd say the response is that the data in our hands resemble what was shared at the time of the Cohort one release, though the magnitude involved is going to be bigger than what appeared there. So what we're examining concerns echocardiographic response, pharmacokinetics and safety. And I believe those are the central items we'll be highlighting as we report on the study.
Jeff Hung
analystLet me make sure I've got this right — when you mention reported, are you talking about, sorry, what I meant was the top line, the figures that appear in, say, the press release? Will you address every one of those points? Or...
Fady Malik
executiveYeah, we'll certainly address every one of those points. As for how much detail, I can't say at this moment; clearly, the press release hasn't been drafted yet. So...
Jeff Hung
analystOkay. Thank you.
Robert Blum
executiveThanks, Jeff.
Robert Blum
executiveHi, Ted. Thanks.
Ted Tentoff
analystHi, everyone. I really appreciate all the updates you provide so regularly. I suppose the sole thing I want to ask about is the study currently underway, and I'm not sure whether there's anything you're able to share, whether about the design or perhaps what your thinking is on that? Thanks.
Robert Blum
executiveAbsolutely. In December we put out a poster concerning the design of COURAGE-ALS, though perhaps I'll have Fady point out its key characteristics.
Fady Malik
executiveThanks. Yes, so COURAGE-ALS is a trial in which patients would be enrolled and assigned randomly to either active or placebo treatment for a period of six months. After that point, those receiving placebo would switch over to the active treatment. Therefore, during the final six months of treatment — 12 full months in total — every patient would be receiving active treatment. The study remained blinded throughout that whole period. The primary endpoints evaluated at six months involve the ALSFRS, or ALS functional rating scale, which had been used as a secondary endpoint in the Fortitude Phase II study. And I believe another important aspect is that there are a few analyses allowing us either to examine futility at an earlier point in the trial's execution or to evaluate whether it should be increased in size if additional powering is required. But perhaps, just given time constraints, I'll stop there.
Robert Blum
executiveHey, Greg. Greg, are you with us?
Greg Suvannavejh
analystYeah. My apologies for that. I appreciate you fielding my question and for the updates. I have 2 questions, if I may. For my first one, perhaps this is actually directed at Ching, and it concerns the guidance. So I understand that guidance is guidance, but it's clear that certain decisions still need to be made regarding the path forward for omecamtiv mecarbil. So I'm simply attempting to gauge what size of swing we might potentially observe once your strategy is set, as we examine our models. I'm just trying to understand how much of your present thinking on omecamtiv mecarbil is already baked into that. $160 million to $170 million net cash utilization? And might it look substantially different once you settle on your plans for the go forward? That's my first question. Then my second question relates to comments that, clearly, you will be meeting with the FDA shortly to learn whether indeed the agency considers the data you've produced to be supportive of a filing on a go-forward basis. And obviously, I think all of us would hope for that. But any early thoughts as to, if that doesn't happen, which other trials you might consider running in order to get it across the finish line? Or is there instead another strategic call about, say, what should be done with the program going forward? Thank you.
Robert Blum
executiveSure. Ching will take your first question, and after that I'll handle the second.
Ching Jaw
executiveWhen it comes to your first question, Greg, providing exact figures at this point feels somewhat premature, since, as we mentioned before, we're looking for possible partners, and our expense outlook could shift based on the financial terms and how costs are divided with those partners. What I can say is that if we end up with a viable route toward commercializing omecamtiv mecarbil, I'd expect a meaningful rise in 2021 spending; however, that won't happen — because by the time we'd be able to assemble our sales team, it would already be late in the year; so keep that in mind when comparing the 2021 change against the possible 2022 increase. My sense is that most of the growth you'll observe will land in 2022. Hopefully that answers it.
Robert Blum
executiveThat's really the key takeaway, I believe. We might revise our guidance partway through the year when it comes to 2021 spending, and whether you'd consider that big or small, it probably won't create the sort of impact you're concerned about for 2021 so much as it could affect how far our cash runway stretches, carrying us through 2022 and on into 2023. So it isn't sufficient to simply devise a go-to-market plan if we lack the means to fund and finance that plan. That's precisely where business development and corporate development are intertwined; taking all of this into account, our intention is to hold that adjustment inside a sensible band, and I'm unable to give you a percentage at this moment, but I'm confident you recognize that numerous factors will influence this, with many pieces in motion right now. Your second question concerned the FDA, and should we receive conclusive feedback at the forthcoming meeting that GALACTIC on its own is not enough to support possible progression toward an NDA filing, first of all, I believe we'd be taken aback; but second, we do have a second Phase III trial already underway, METEORIC. As we noted, it will finish enrollment during the first half of this year, and it could quite possibly function as a second pivotal study should one be needed. We have a study of more than 8,000 patients with a p less than 0.05. So we don't anticipate that, that it should be needed, yet that could be the second Phase III trial that might then be called for. And should it not be that one, then we would anticipate that another trial might be run in this population that we believe was the most responsive to omecamtiv mecarbil in GALACTIC. But clearly, that's an entirely different situation, and it would demand extra resources and time, and that isn't what we currently anticipate.
Greg Suvannavejh
analystUnderstood. Thank you so much.
Robert Blum
executiveThank you.
Robert Blum
executiveHello, Carter.
Carter Gould
analystHi, everyone. Good evening. I've been listening for a long while, but this is my first time asking a question. I suppose, returning to what you said about 274 compared with 271, what I take away is that for the immediate future, there's a clear emphasis on 274, though I gather matters remain — every possibility is still open when you consider splitting up indications, I suppose. Is that how I should read it? Have you reached any conclusions about choosing not to go after indications that overlap between these assets, I suppose, in the short term? And then, as a second question, perhaps, Robert, you mentioned possible co-promotion arrangements for omecamtiv. Yet at the same time, you brought up all the ways commercial infrastructure and synergies could be leveraged toward a growing CV franchise. So I suppose I'm simply attempting to grasp what the — when you think about how you'd decide on a copromote, what might push you toward making that choice as opposed to not making it? Thank you.
Robert Blum
executiveCertainly. To begin with, no conclusions have been reached about avoiding overlapping indications, but we are examining CK-274 in obstructive HCM. And as you're aware, it comes after excellent work done by Myokardia on mavacamten, which is now with BMS. There's much for us to discover about where, as a next-generation compound, we can move the field forward. And being a fast follower means there's benefit in studying closely how this category develops; so, as you may have seen, BMS issued some announcements concerning its interest in nonobstructive HCM and likewise in HEpEF; and our view is that as they proceed with mavacamten in those indications, that will shed light on how we may decide to proceed with CK-274 and CK-271; doing all of it simultaneously isn't something we can afford, so prioritization is necessary, and we're examining nonobstructive disease, and we're examining hfpef while considering how we might, using a molecule such as CK-274 or CK 271 or honestly, we also have additional compounds coming out of research, how we might be — if not first to market, how we might become a potential best-in-class? And that's the point where we want to ensure we're being smart regarding our pipeline of cardiac myosin inhibitors. I hope that answers your question; as for partnering in co-promotion, I'll simply note that we're considering where our business could be built, while acknowledging that not everything we want can be built. Certain things must be rented as we then generate positive marketing contribution and positive cash flows so they can be funneled back into expanding and scaling up our commercialization. My expectation is that we won't enter Europe on our own. My expectation is that, that will be built alongside a co-promotion partner. Within America, my goal is to ensure we hold the top position in the sector where we believe our efforts can achieve the greatest results at the best rate of return, which is institutional care. Yet when we extend our sales force past those medical centers and integrated systems out into the community, certain clinics sit closer to us and more often handle patients with advanced heart failure, while others are farther away, and for some of those efforts we could potentially gain from bringing in a co-promotion ally as we eventually grow our commercial operation. Once more, all of this must be weighed alongside whatever we are pursuing on the digital front, acknowledging our potential to lead there when it comes to heart failure. So each of these elements plays a role in how we approach co-promotion and franchise development. What we truly aim for, though, is confidence that we have people physically present in those heart failure hospitals with high volumes, which are likewise the HCM centers with high volumes, and serving as the core of our approach, that will be vital. Does that work?
Carter Gould
analystThank you.
Robert Blum
executiveThank you, Carter.
Robert Blum
executiveAppreciate it, operator. I want to thank my coworkers, and I also want to thank each of you joining this call for taking part in these conversations. I believe we've explained why we see 2021 as potentially a year of transformation for Cytokinetics. That prospect has us quite enthusiastic. We feel good about what this could mean — not just for omecamtiv mecarbil, but also for the other drug candidates in our pipeline and for our organization — and we're eager to share news about how things are going. So with that, operator, let's wrap up this call.
Operator
operatorEveryone, that brings us to the end of today's call. We appreciate your joining us. You're free to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.